MD vs. GILD

Last updated Apr 1, 2026

Compare and contrast key facts about MEDNAX, Inc. (MD) and Gilead Sciences, Inc. (GILD).

Performance

MD vs. GILD - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in MEDNAX, Inc. (MD) and Gilead Sciences, Inc. (GILD). The values are adjusted to include any dividend payments, if applicable.

MD vs. GILD - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
MD MEDNAX, Inc.	-0.00%	63.03%	41.08%	-37.42%	-45.39%	10.88%	-11.69%	-15.79%	-38.25%	-19.83%
GILD Gilead Sciences, Inc.	14.19%	36.59%	18.68%	-1.99%	23.63%	29.95%	-6.70%	7.88%	-9.92%	2.96%

Fundamentals

Market Cap MD : $1.81B GILD : $174.63B
EPS MD : $1.93 GILD : $6.79
PE Ratio MD : 11.07 GILD : 20.54
PEG Ratio MD : 1.35 GILD : 0.05
PS Ratio MD : 0.96 GILD : 5.94
PB Ratio MD : 2.09 GILD : 7.72
Total Revenue (TTM) MD : $1.91B GILD : $29.44B
Gross Profit (TTM) MD : $367.72M GILD : $23.79B
EBITDA (TTM) MD : $227.04M GILD : $12.90B

Returns By Period

Over the past 10 years, MD has underperformed GILD with an annualized return of -10.46%, while GILD has yielded a comparatively higher 7.74% annualized return.

MD

• 1D: 2.84%
• 1M: 7.76%
• YTD: -0.00%
• 6M: 27.70%
• 1Y: 47.62%
• 3Y*: 12.78%
• 5Y*: -3.34%
• 10Y*: -10.46%

GILD

• 1D: 2.22%
• 1M: -5.90%
• YTD: 14.19%
• 6M: 27.11%
• 1Y: 27.69%
• 3Y*: 22.97%
• 5Y*: 20.37%
• 10Y*: 7.74%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

MD vs. GILD — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MD

MD Risk / Return Rank: 76
MD Sharpe Ratio Rank: 76
MD Sortino Ratio Rank: 76
MD Omega Ratio Rank: 74
MD Calmar Ratio Rank: 79
MD Martin Ratio Rank: 75

GILD

GILD Risk / Return Rank: 74
GILD Sharpe Ratio Rank: 74
GILD Sortino Ratio Rank: 70
GILD Omega Ratio Rank: 65
GILD Calmar Ratio Rank: 78
GILD Martin Ratio Rank: 80

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

MD vs. GILD - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for MEDNAX, Inc. (MD) and Gilead Sciences, Inc. (GILD). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	MD	GILD	Difference
Sharpe ratio Return per unit of total volatility	1.04	0.96	+0.09
Sortino ratio Return per unit of downside risk	1.85	1.55	+0.30
Omega ratio Gain probability vs. loss probability	1.24	1.18	+0.06
Calmar ratio Return relative to maximum drawdown	2.16	2.03	+0.13
Martin ratio Return relative to average drawdown	4.62	5.55	-0.93
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

MD vs. GILD - Sharpe Ratio Comparison

The current MD Sharpe Ratio is 1.04, which is comparable to the GILD Sharpe Ratio of 0.96. The chart below compares the historical Sharpe Ratios of MD and GILD, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	MD	GILD	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.04	0.96	+0.09
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.08	0.86	-0.93
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.23	0.30	-0.53
Sharpe Ratio (All Time) Calculated using the full available price history	0.09	0.39	-0.30

Correlation

The correlation between MD and GILD is 0.23, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

MD vs. GILD - Dividend Comparison

MD has not paid dividends to shareholders, while GILD's dividend yield for the trailing twelve months is around 2.29%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
MD MEDNAX, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
GILD Gilead Sciences, Inc.	2.29%	2.57%	3.33%	3.70%	3.40%	3.91%	4.67%	3.88%	3.65%	2.90%	2.57%	1.27%

Drawdowns

MD vs. GILD - Drawdown Comparison

The maximum MD drawdown since its inception was -92.08%, which is greater than GILD's maximum drawdown of -70.83%. Use the drawdown chart below to compare losses from any high point for MD and GILD.

Drawdown Indicators

	MD	GILD	Difference
Max Drawdown Largest peak-to-trough decline	-92.08%	-70.83%	-21.25%
Max Drawdown (1Y) Largest decline over 1 year	-23.65%	-13.77%	-9.88%
Max Drawdown (5Y) Largest decline over 5 years	-80.74%	-26.59%	-54.15%
Max Drawdown (10Y) Largest decline over 10 years	-91.13%	-36.01%	-55.12%
Current Drawdown Current decline from peak	-74.97%	-10.04%	-64.93%
Average Drawdown Average peak-to-trough decline	-38.54%	-22.20%	-16.34%
Ulcer Index Depth and duration of drawdowns from previous peaks	11.06%	5.04%	+6.02%

Volatility

MD vs. GILD - Volatility Comparison

MEDNAX, Inc. (MD) has a higher volatility of 8.29% compared to Gilead Sciences, Inc. (GILD) at 6.41%. This indicates that MD's price experiences larger fluctuations and is considered to be riskier than GILD based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	MD	GILD	Difference
Volatility (1M) Calculated over the trailing 1-month period	8.29%	6.41%	+1.88%
Volatility (6M) Calculated over the trailing 6-month period	32.97%	18.97%	+14.00%
Volatility (1Y) Calculated over the trailing 1-year period	45.85%	29.00%	+16.85%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	44.70%	23.93%	+20.77%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	45.77%	25.63%	+20.14%

Financials

MD vs. GILD - Profitability Comparison

The chart below illustrates the profitability comparison between MEDNAX, Inc. and Gilead Sciences, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

MD - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, MEDNAX, Inc. reported a gross profit of 0.00 and revenue of 493.77M. Therefore, the gross margin over that period was 0.0%.

GILD - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Gilead Sciences, Inc. reported a gross profit of 6.88B and revenue of 7.93B. Therefore, the gross margin over that period was 86.8%.

MD - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, MEDNAX, Inc. reported an operating income of 48.79M and revenue of 493.77M, resulting in an operating margin of 9.9%.

GILD - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Gilead Sciences, Inc. reported an operating income of 2.96B and revenue of 7.93B, resulting in an operating margin of 37.4%.

MD - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, MEDNAX, Inc. reported a net income of 33.68M and revenue of 493.77M, resulting in a net margin of 6.8%.

GILD - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Gilead Sciences, Inc. reported a net income of 2.18B and revenue of 7.93B, resulting in a net margin of 27.6%.